Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study

por Aggarwal, Neil R, Molina, Kyle C, Beaty, Laurel E, Bennett, Tellen D, Carlson, Nichole E, Mayer, David A, Peers, Jennifer L, Russell, Seth, Wynia, Matthew K, Ginde, Adit A
Publicado 2023

Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase

por Aggarwal, Neil R., Beaty, Laurel E., Bennett, Tellen D., Carlson, Nichole E., Mayer, David A., Molina, Kyle C., Peers, Jennifer L., Russell, Seth, Wynia, Matthew K., Ginde, Adit A.
Publicado 2023

Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5

por Molina, Kyle C., Kennerley, Victoria, Beaty, Laurel E., Bennett, Tellen D., Carlson, Nichole E., Mayer, David A., Peers, Jennifer L., Russell, Seth, Wynia, Matthew K., Aggarwal, Neil R., Ginde, Adit A.
Publicado 2023

Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients

por Douin, David J., Wogu, Adane F., Beaty, Laurel E., Carlson, Nichole E., Bennett, Tellen D., Aggarwal, Neil R., Mayer, David A., Ong, Toan C., Russell, Seth, Steele, Jeffrey, Peers, Jennifer L., Molina, Kyle C., Wynia, Matthew K., Ginde, Adit A.
Publicado 2022